How daraxonrasib uses cyclophilin A to engage active RAS.

How Daraxonrasib works

Daraxonrasib (RMC-6236) acts through a three-component complex involving cyclophilin A and active RAS. Showing the partner protein makes its mechanism more intelligible than depicting a small molecule simply attaching to RAS.

1. Recruit cyclophilin A. Daraxonrasib binds cyclophilin A, forming a two-component complex.
2. Engage active RAS. That complex binds the GTP-bound state of RAS.
3. Inhibit signaling. The resulting tri-complex blocks downstream effector interactions and promotes conversion to the inactive GDP-bound state through GTP hydrolysis, as described in section 12.1 of the RASONQUE prescribing information.

The molecular view uses PDB 9BG6, an experimental complex of daraxonrasib, KRAS G12V and cyclophilin A. Its deposited nucleotide is a GTP analogue; the static structure does not show a hydrolysis reaction.

A structure can establish a binding arrangement without measuring a drug’s journey through tissue. This example makes that distinction explicit: experimental molecular coordinates support the structural view; tissue layouts and animated approaches are explanatory.

See the binding sequence in 20 seconds

Daraxonrasib binds cyclophilin A; the pair engages active RAS and blocks effector binding.

Tumor context, molecular recognition and cellular action

Four panels connect pancreatic tumor tissue, active RAS at the cell membrane, the experimental RAS–cyclophilin A–daraxonrasib complex, and a schematic of effector blockade and GTP hydrolysis.

Survival and response in RASolute 302

The figure compares daraxonrasib with physician-choice chemotherapy in previously treated metastatic pancreatic cancer, showing overall survival, progression-free survival and objective response, alongside confidence intervals and selected safety warnings.

The evidence brief explains the trial population, endpoints and risks, and distinguishes the overall randomized population from the RAS G12 subgroup.

Scientific sources and representation limits

The mechanism summary below the film is based on the primary sources linked here. The source notes describe how those references relate to the visuals.

• RASONQUE prescribing information: mechanism, clinical studies and safety
• Daraxonrasib–KRAS G12V–cyclophilin A experimental structure, PDB 9BG6
• Molecular rendering and representation notes
• Clinical-results figure sources and interpretation

The experimental structure supports the final binding arrangement. The approach of the molecules, tumor layout and changes in cell populations are authored for explanation. Clinical outcomes come from the cited clinical evidence, not from running the scene.

How this example could support a program

A content foundation for physician education on RAS inhibition, or a separately scoped investor and partner communication program. An audience-specific version can introduce the treatment rationale before a meeting and provide a resource for the scientific questions that follow.